메뉴 건너뛰기




Volumn 8, Issue 2, 2013, Pages 223-225

Call for fellowship programs in stem cell-based regenerative and cellular medicine: New stem cell training is essential for physicians

Author keywords

cellular therapy; fellowship training; physician training; regenerative medicine; stem cells; US FDA

Indexed keywords

CELL ISOLATION; EXPERIMENTAL THERAPY; GOOD MANUFACTURING PRACTICE; HEALTH PROGRAM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MEDICAL EDUCATION; MEDICAL SOCIETY; MESENCHYMAL STEM CELL; PHYSICIAN; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; STEM CELL GENE THERAPY; STEM CELL TRANSPLANTATION; UNITED STATES;

EID: 84874878602     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.13.1     Document Type: Review
Times cited : (19)

References (5)
  • 1
    • 84864422878 scopus 로고    scopus 로고
    • FDA's claims over stem cells upheld
    • Cyranoski D. FDA's claims over stem cells upheld. Nature 488(7409), 14 (2012).
    • (2012) Nature , vol.488 , Issue.7409 , pp. 14
    • Cyranoski, D.1
  • 2
    • 77955906240 scopus 로고    scopus 로고
    • FDA challenges stem-cell clinic
    • Cyranoski D. FDA challenges stem-cell clinic. Nature 466(7309), 909 (2010).
    • (2010) Nature , vol.466 , Issue.7309 , pp. 909
    • Cyranoski, D.1
  • 3
    • 84864886460 scopus 로고    scopus 로고
    • Texas legitimizes path around FDA oversight
    • DeFrancesco L. Texas legitimizes path around FDA oversight. Nat. Biotechnol. 30(5), 379 (2012).
    • (2012) Nat. Biotechnol. , vol.30 , Issue.5 , pp. 379
    • Defrancesco, L.1
  • 4
    • 84859930680 scopus 로고    scopus 로고
    • Stem cells. Texas Medical Board approves rules for controversial treatment
    • Kaiser J. Stem cells. Texas Medical Board approves rules for controversial treatment. Science 336(6079), 284 (2012).
    • (2012) Science , vol.336 , Issue.6079 , pp. 284
    • Kaiser, J.1
  • 5
    • 84873025922 scopus 로고    scopus 로고
    • Communications with the Food and Drug Administration on the development pathway for a cell-based therapy: Why, what, when, and how?
    • Feigal EG, Tsokas K, Zhang J, Cromer MV, Whittlesey KJ, Werner MJ. Communications with the Food and Drug Administration on the development pathway for a cell-based therapy: why, what, when, and how? Stem Cells Transl. Med. 1(11), 825-832 (2012).
    • (2012) Stem Cells Transl. Med. , vol.1 , Issue.11 , pp. 825-832
    • Feigal, E.G.1    Tsokas, K.2    Zhang, J.3    Cromer, M.V.4    Whittlesey, K.J.5    Werner, M.J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.